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Background: Fibrillary glomerulonephritis (FGN) is a rare primary glomerular disease that seldom coexists with
other diseases. Membranoproliferative glomerulonephritis is a pathologic finding of renal lesions associated with
IgM-secreting monoclonal proliferations. We present a case study of a patient with unusual simultaneous FGN and
IgM-related renal disorder in nonmalignant monoclonal IgM gammopathy.
Case presentation: A 63-year-old male presented with nephrotic syndrome and elevated serum creatinine levels.
Laboratory examination revealed elevated levels of serum IgM and low C3 levels. Serum and urine immunofixation
electrophoresis showed a monoclonal IgM with a kappa light chain. A bone marrow biopsy revealed less than 5 %
bone marrow infiltration by lymphoplasmacytic lymphoma, and a renal biopsy revealed mesangiocapillary
glomerulonephritis on light microscopy. Immunofluorescent and immunohistochemical staining indicated granular
deposits of immunoglobulin G in the mesangium and granular deposits of immunoglobulin M and κ light chains
along the capillary wall. Electron microscopy revealed randomly arranged nonbranching fibrils of approximately
15 nm in diameter in the glomerular mesangium and subendothelial electron-dense deposits. According to these
results, we confirmed FGN and membranoproliferative glomerulonephritis, which were attributed to monoclonal
IgM deposits.
Conclusion: To the best of our knowledge, this is the first report of simultaneous FGN and membranoproliferative
glomerulonephritis in nonmalignant IgM monoclonal gammopathy.
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The term “fibrillary glomerulonephritis” (FGN) was in-
troduced by Alpers et al in 1987 to characterize the
glomerular accumulation of nonbranching, randomly
arranged fibril, which differ from amyloid deposits in
their large size and lack of reactivity to Congo red [1].
FGN is a rare disorder, diagnosed in less than 1 % of
renal biopsies and usually presents with renal insuffi-
ciency, nephrotic range proteinuria, and hematuria [2].* Correspondence: shoushan.chiang@gmail.com
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ment in IgM monoclonal gammopathy is typically found
in patients with the malignant disease, Waldenström’s
macroglobulinemia, which is associated with B-cell
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the deposition of monoclonal IgM and light chains on
the mesangium and glomerular capillary wall [5, 6]. In
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nant IgM/κ gammopathy who developed nephrotic syn-
drome associated with FGN and the renal deposition of
IgM and κ light chains.Case presentation
A 63-year-old man presented at our nephrologic out-
patient clinic with progressive bilateral leg edema and
foamy urine, which he had experienced for 1 month. He
was hospitalized for alcoholic pancreatitis in 1999 but
not regularly followed up by our hospital after discharge.
Physical examination of the patient revealed a blood
pressure of 150/85 mmHg, blood temperature of 36.5 °C,
and pulse rate of 78 beats/minute; the grading scale for
pitting edema was 3+. The laboratory results were as
follows: blood urea nitrogen, 26 mg/dL; serum cre-
atinine, 1.8 mg/dL; albumin, 3.1 g/dL; hemoglobin,
12.4 g/dL and platelets, 212 × 103 / uL. Urinalysis re-
vealed 2+ occult blood, 3+ protein, and 5-7 red blood
cells/high power field; the 24-h protein excretion was
5.7 g/day. Serum immunoglobulin (Ig) and serum
complement tests yielded high IgM (498 mg/dL), low
C3 and IgG (73 and 688 mg/dL, respectively), and
normal IgA and C4 levels. Serum and urine immuno-
fixation electrophoresis showed a monoclonal IgM-
bearing kappa light chain. The urinary Bence Jones
protein was negative. The rheumatoid factor, antinu-
clear antibody, cryoglobulin, and other autoantibodies
were negative. Serum antibodies against HIV, hepatitis
B and C were all negative. A bone marrow biopsy re-
vealed hypocellularity with normal maturation of mye-
loid series, and less than 5 % of the cells had positive
immunohistochemical staining of CD138/syndecan-1
plasma cells.
Renal sonography showed that both kidneys were
enlarged. Chest and abdominal computerized tomographyFig. 1 Light microscopic features of membranoproliferative glomerulonephritis
thickened (periodic acid-Schiff). (b) Glomerular capillary walls exhibit thickened aruled out organomegaly and lymphadenopathy. A whole
body bone X-ray revealed no lytic bone lesions.
Light microscopy of the renal biopsy revealed nodular
segmental glomerulosclerosis with mesangial cell prolif-
eration and mesangial matrix expansion (Fig. 1a) in 9 of
the 11 glomeruli; the other 2 glomeruli are global scler-
oses. In addition, focal segmental double-contoured ca-
pillary walls were observed, and mild tubular atrophy,
interstitial fibrosis, and mononuclear cell infiltration
were found (Fig. 1b). Congo red staining was negative.
We performed immunofluorescence studies, observing
a strong positive staining for IgM with a diffuse, global,
granular, and capillary pattern (Fig. 2a) ; positive staining
for IgG with a diffuse, granular, and mesangial pattern
(Fig. 2b); and positive staining for C3 with a diffuse,
segmental, and granular pattern in the mesangium and
along the capillary wall (Fig. 2c). Immunohistochemistry
of the light chains revealed κ positive along the capillary
wall. Electron microscopy showed podocyte foot process
effacement and microvillus transformation. Electron-
dense materials were deposited in the subendothelial
area and limited intracapillary monoclonal deposits were
observed (Fig. 3a). Irregular accumulations of randomly
arranged nonbranching fibrils, approximately 15 nm in
diameter, were found in the glomerular mesangium
(Fig. 3b, c). These findings confirmed the diagnosis of
FGN with membranoproliferative glomerulonephritis in
nonmalignant IgM monoclonal gammopathy.
The patient was treated initially with diuretics, angioten-
sin receptor blockers, 0.5 mg/kg of prednisolone per day,
and 1.5 mg/kg of cyclophosphamide per day. Because
steroid-induced diabetes occurred, we halved the steroid
dose within the first 3 months. After 6 months, serum
creatinine levels were maintained at 1.8 mg/dL and the
24-h protein excretion decreased to 1.8 g/day. 1 year
later, the patient experienced herpes zoster; therefore, we
discontinued cyclophosphamide treatment. However, the. (a) The mesangium is expanded and the glomerular capillary walls appear
nd segmental double contours (methenamine silver)
Fig. 2 Immunofluorescent staining on fibrillary glomerulonephritis and renal involvement of IgM gammopathy. (a) Diffuse granular deposits of IgM along
the glomerular capillary walls. (b) Smudged diffuse granular mesangial deposits of IgG. (c) Diffuse segmental granular deposits of C3 on the mesangium
and along the glomerular capillary walls
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second year after diagnosis and advanced to end-stage renal
disease (ESRD) without dialysis the third year after
diagnosis.Conclusions
FGN, first described by Rosenmann and Eliakim in 1977
[8], is a rare primary glomerulonephritis diagnosed by
the ultrastructural features of nonbranching random fi-
brils measuring 10-30 nm in diameter. The fibrils are de-
posited in the mesangium, the glomerular basement
membranes, or both. The light microscopic findings are
highly variable, and most exhibit mesangial expansion
and hypercellularity with or without the duplication of
glomerular basement membranes. Immunofluorescence
staining is almost consistently positive for IgG, C3, and
both κ and λ chains, indicating polyclonal deposits.Fig. 3 Electron microscopic features of subendothelial deposits and fibrillar
subendothelial deposits and small intracapillary deposits. (b) Electron microgr
(c) Irregular accumulations of randomly arranged nonbranching fibrils in the mWeak staining for IgM, IgA, and C1q has been reported
in a few cases [2, 9, 10].
Our patient with FGN exhibited various atypical charac-
teristics, including a strong positive immunofluorescent
intensity of IgM along the glomerular capillary wall; the
presence of IgM κ, as detected by immunofixation electro-
phoresis, and hypocomplementemia. In a large single-
center series of 66 FGN cases, 47 % of the cases were
weakly positive for IgM according to the immunofluores-
cence stain, and the mean intensity of the positive cases
was 1.0+. Of the 11 patients exhibiting a positive M-spike,
all were IgG with or without light chains according to
immunofixation electrophoresis. Only one patient in this
study had hypocomplementemia [11]. Only one case of
FGN with unusual IgM deposits and hypocomplemente-
mia has been reported in the English literature. A 12-year-
old girl who presented with nephrotic-nephritic syndrome
had IgM deposits in the mesangium and randomlyy glomerulonephritis. (a) Electron micrograph image revealing granular
aph image showing infiltration of fibrillar materials in the mesangium.
esangium
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gium, and the subendothelial and subepithelial area of
capillary loops. However, the patient did not have elevated
levels of serum IgM or positive IgM detected by urine
protein electrophoresis [12].
At an international workshop on Waldenström’s
macroglobulinemia, 4 categories of IgM monoclonal gam-
mopathies were proposed. Patients with bone marrow
infiltration by lymphoplasmacytic lymphoma who (1)
might or might not (2) have symptoms caused by IgM are
categorized as having symptomatic or asymptomatic
Waldenström’s disease, respectively. (3) Patients with
symptoms attributable to IgM but with no bone marrow
infiltration are classified as having IgM-related disorder.
(4) Patients with IgM monoclonal gammopathy but no
bone marrow infiltration or IgM-related symptoms are
classified as having MGUS [3].
The incidence of renal complications of malignant IgM-
secreting proliferation is rare, and renal involvement in
IgM monoclonal disorders is generally described in patients
with Waldenström’s macroglobulinemia [6]. The typical
pathologic findings of Waldenström’s macroglobulinemia-
related nephropathies include intracapillary deposits of IgM
with or without cryoglobulinemia, light chain amyloidosis,
and infiltration of the interstitium by neoplastic lympho-
plasmacytic cells [5]. Glomerular involvement was noted in
some patients with typical mesangioproliferative or mesan-
giocapillary glomerulonephritis with IgM deposits in the
mesangium and/or along the glomerular basement mem-
brane [13]. Upon immunofluorescence stain, the deposits
of IgM and the single light chain isotype were consistent
with circulating M components. Electron microscopy re-
vealed that the subendothelial deposits contain nonamyloid
fibrillar materials [14].
Our patient had renal lesions associated with IgM-
secreting monoclonal proliferations but did not fulfill
the criteria for having Waldenström’s macroglobuline-
mia. Audard et al. revisited the spectrum of renal lesions
occurring in patients with a circulating monoclonal IgM
and kidney disease related to B cell proliferation. Of the
14 patients examined, 5 patients had intracapillary IgM
monoclonal deposits disease, 3 patients had a neoplastic
lymphoplasmacytic infiltration of the interstitium, 3 pa-
tients had membranoproliferative glomerulonephritis, 2
patients had amyloidosis, and 1 patient had acute tubu-
lar necrosis. According to immunologic data, only 3 pa-
tients had low blood complement C3, C4, and CH50
levels; all these patients were diagnosed with Walden-
ström’s macroglobulinemia [15]. Our patient had circu-
lating monoclonal IgM and a low blood complement C3
level but no bone marrow infiltrations. A kidney disease
related to B- cell proliferation is membranoproliferative
glomerulonephritis, but unusual nonbranching randomly
fibrils is found in the mesangium.Regarding treatment, although no effective therapy has
been established for FGN, some clinicians have treated the
disease according to pathologic findings. Cyclosporine has
been used successfully to treat patients with a membranous
pattern, and rituximab has been used successfully to treat
patients with an MPGN pattern [9, 16]. In previous inves-
tigations, the prognosis of patients with FGN has been
poor, and 40 %-50 % of such patients have developed
ESRD within 6 years of presentation [2, 17]. Treatment
recommendations for Waldenström’s macroglobulinemia
were established in the aforementioned international
workshop. Patients with Waldenström’s macroglobuline-
mia should be treated when their hemoglobin level is less
than 100 g/L, their platelet count is less than 100 × 109/L,
and they present with bulky disease, symptomatic hyper-
viscosity, severe neuropathy, amyloidosis, cryoglobuline-
mia, cold-agglutinin disease, or evidence of disease
transformation [3, 6]. Several drugs are used for frontline
therapy, such as alkylators (ie, chlorambucil), nucleoside
analogues (ie, fludarabine) and monoclonal antibodies
(ie, rituximab), and combination therapies include cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone.
Other alternative treatments included autologous trans-
plantation, thalidomide or thalidomide plus steroids, and
alemtuzumab [6]. Rituximab was suggested for our pa-
tient, but his condition did not satisfy the criteria for
health insurance payment. Finally, in addition to conserva-
tive treatment with angiotensin receptor blocker and diur-
etic drugs, he was treated with cyclophosphamide and
prednisolone. Nevertheless, he progressed to ESRD after
2 years of treatment.
In summary, we report a rare simultaneous occur-
rence of FGN and membranoproliferative glomerulo-
nephritis attributed to IgM/κ deposits in a patient
with nonmalignant IgM monoclonal gammopathy.
This patient exhibited a wide spectrum of renal le-
sions caused by IgM-secreting monoclonal prolifera-
tions, and renal prognosis was as poor as that for
FGN.
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